Oral Dosage Form New Animal Drugs; Albendazole Suspension

FederalRegulations

Ask Donna

How this section applies to your facts.

Federal Register › Vol. 64 › 64 FR 1503

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 520 and 556

Oral Dosage Form New Animal Drugs; Albendazole Suspension

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal

drug regulations to reflect approval of a supplemental new animal drug

application (NADA) filed by Pfizer, Inc. The supplemental NADA provides

for anthelmintic use of the 11.36 percent albendazole suspension in

sheep. Based on FDA's review of the data and information in the NADA, a

tolerance for drug residues in muscle and an acceptable daily intake

(ADI) are established.

EFFECTIVE DATE: January 11, 1999.

FOR FURTHER INFORMATION CONTACT: Estella Z. Jones, Center for

Veterinary Medicine (HFV-135), Food and Drug Administration, 7500

Standish Pl., Rockville, MD 20855, 301-827-7575.

SUPPLEMENTARY INFORMATION: Pfizer, Inc., 235 East 42d St., New York,

NY 10017-5755, filed supplemental NADA 110-048 that provides for oral

use of Valbazen (albendazole) 11.36 percent suspension in

sheep as an anthelmintic. Currently, the 11.36 percent drug is approved

for use in cattle in NADA 110-048, and the 4.55 percent drug is

approved for use in sheep in NADA 140-934. Supplemental NADA 110-048 is

approved as of December 2, 1998, and the regulations are amended in

Sec. 520.45a(b)(1) (21 CFR 520.45a(b)(1)) to reflect the approval.

In addition, FDA reviewed the data concerning anthelmintic use of

albendazole in Pfizer, Inc.'s NADA 110-048 for cattle and NADA 140-934

for sheep to determine a tolerance for residues of albendazole in

muscle of cattle and sheep. Based on this review, a tolerance of 50

parts per billion for albendazole 2-aminosulfone in both cattle and

sheep muscle is established. Additionally, the previously established

ADI of 5 micrograms per kilogram of body weight per day is codified.

Also, the regulations are amended in 21 CFR 556.34 to reflect the ADI

and the muscle tolerance.

Furthermore, Sec. 520.45a is amended editorially in paragraph

(a)(4) by removing the ``(i)'' after the ``(4)'' and adding the ``(i)''

in place of the ``(1)'' following the paragraph heading, and by

removing paragraph (a)(4)(i)(2).

In accordance with the freedom of information provisions of 21 CFR

part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness

data and information submitted to support approval of this application

may be seen in the Dockets Management Branch (HFA-305), Food and Drug

Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852,

between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action

is of a type that does not individually or cumulatively have a

significant effect on the human environment. Therefore, neither an

environmental assessment nor an environmental impact statement is

required.

List of Subjects

21 CFR Part 520

Animal drugs.

21 CFR Part 556

Animal drugs, Foods.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under

authority delegated to the Commissioner of Food and Drugs and

redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and

556 are amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as

follows:

Authority: 21 U.S.C. 360b.

2. Section 520.45a is amended by redesignating the heading of

paragraph (a)(4)(i) as the heading of paragraph (a)(4), by

redesignating paragraph (a)(4)(i)(1) as paragraph (a)(4)(i), by

removing paragraph (a)(4)(i)(2), and by revising paragraph (b)(1) to

read as follows:

Sec. 520.45a Albendazole suspension.

(a) * * *

(4) Conditions of use in cattle--(i) Amount. * * *

(b)(1) Specifications. The product contains 4.55 or 11.36 percent

albendazole.

* * * * *

PART 556--TOLERANCES FOR RESIDUES OF NEW ANIMAL DRUGS IN FOOD

3. The authority citation for 21 CFR part 556 continues to read as

follows:

Authority: 21 U.S.C. 342, 360b, 371.

4. Section 556.34 is revised to read as follows:

Sec. 556.34 Albendazole.

(a) Acceptable daily intake (ADI). The ADI for total residues of

albendazole is 5 micrograms per kilogram of body weight per day.

(b) Tolerances--(1) Cattle. A tolerance is established for

albendazole 2-aminosulfone (marker residue) in liver (target tissue) of

0.2 part per million and in muscle of 0.05 part per million.

(2) Sheep. A tolerance is established for albendazole 2-

aminosulfone (marker residue) in liver (target tissue) of 0.25 part per

million and in muscle of 0.05 part per million.

Dated: December 17, 1998.

Andrew J. Beaulieu,

Acting Director, Office of New Animal Drug Evaluation, Center for

Veterinary Medicine.

[FR Doc. 99-449 Filed 1-8-99; 8:45 am]

BILLING CODE 4160-01-F

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.